Given the multifaceted advantages of antisense oligonucleotide therapeutics, the field has witnessed an increase in
the number of players involved in the development of such solutions. The domain
features the presence of over 30 companies which are involved in the
development of over 170 antisense oligonucleotide drugs.
Majority of the developers (55%) of antisense
oligonucleotide therapeutics are start-ups or small-sized (less than 50 employees), followed by 29% large (501-5000 employees) and 16% mid-sized
companies (51-500 employees). Notable
examples of the start-ups in the antisense oligonucleotide domain include (in alphabetical order) Atlantic
Healthcare, Dynacure, Isarna Therapeutics, and Sterna Biologicals.
Additionally, it is worth highlighting that seven molecules
(capturing 4% of the share), namely, Spinraza (by Ionis Pharmaceuticals),
Vyondys 53 (Sarepta Therapeutics), Tegsedi (Ionis Pharmaceuticals), Waylivra
(Ionis Pharmaceuticals), Viltepso (Nippon Shinyaku) and Exondys 51 (Sarepta
Therapeutics) have been commercialized till date and over 60% molecules are
currently in advanced stages of development (phase II and above). In addition,
majority of the therapies (28) are designed for administration through
subcutaneous route. The subcutaneous route of administration facilitates rapid
onset of the therapeutic action that can be extended to a longer duration.
Examples of late stage molecules that are being administered subcutaneously
include (in alphabetical order) ATL1102 (Antisense Therapeutics),
IONIS-FB-LRx (Ionis Pharmaceuticals) and Pelacarsen (Novartis). Further, the
second most preferred route of administration is intravenous route. This route
of delivery gives reproducible effects and the administered dose directly
reaches systemic circulation.
For more information, please click on the following:
https://www.rootsanalysis.com/reports/antisense-oligonucleotide-therapeutics-market.html